Resistance and escape from antiangiogenesis therapy: Clinical implications and future strategies

Journal of Clinical Oncology

Volumn 30, Issue 32, 2012, Pages 4026-4034

  Bottsford Miller, Justin N ^a   Coleman, Robert L ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CABOZANTINIB; CARBOPLATIN; CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; OSTEOPONTIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROSTAGLANDIN E2; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ASTROCYTOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; ENDOTHELIUM CELL; GENOMIC INSTABILITY; GLIOBLASTOMA; HUMAN; HYPOXIA; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REOXYGENATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CLONING, MOLECULAR; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIVIDUALIZED MEDICINE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84869407359     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.41.9242     Document Type: Review

References (121)

1. Folkman J, Merler E, Abernathy C, et al: Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133:275-288, 1971
2. Potente M, Gerhardt H, Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell 146:873-887, 2011
3. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
4. Spannuth WA, Sood AK, Coleman RL: Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 5:194-204, 2008
5. Eskander RN, Randall LM: Bevacizumab in the treatment of ovarian cancer. Biologics 5:1-5, 2011
6. Beal K, Abrey LE, Gutin PH: Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches. Radiat Oncol 6:2, 2011
7. Casanovas O, Hicklin DJ, Bergers G, et al: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309, 2005
8. Xu L, Duda DG, di Tomaso E, et al: Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 69:7905-7910, 2009
9. Hu DE, Fan TP: Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A. Br J Pharmacol 114:262-268, 1995
10. Rosen LS: Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9:36-44, 2002 (suppl)
11. Jackson DB, Sood AK: Personalized cancer medicine-advances and socio-economic challenges. Nat Rev Clin Oncol 8:735-741, 2011
12. Burger RA, Brady MF, Bookman MA, et al: Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473-2483, 2011
13. Perren TJ, Swart AM, Pfisterer J, et al: A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484-2496, 2011
14. Scagliotti G, Novello S, von Pawel J, et al: Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835-1842, 2010
15. Barrios CH, Liu MC, Lee SC, et al: Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat 121:121-131, 2010
16. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011
17. Fernando NT, Koch M, Rothrock C, et al: Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by upregulation of multiple proangiogenic factors. Clin Cancer Res 14:1529-1539, 2008
18. Ebos JM, Lee CR, Christensen JG, et al: Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 104:17069-17074, 2007
19. Lieu C, Heymach J, Overman M, et al: Beyond VEGF: Inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 17:6130-6139, 2011
20. Greenhalgh DG, Sprugel KH, Murray MJ, et al: PDGF and FGF stimulate wound healing in the genetically diabetic mouse. Am J Pathol 136:1235-1246, 1990
21. Tassi E, Al-Attar A, Aigner A, et al: Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein. J Biol Chem 276:40247-40253, 2001
22. Kopetz S, Hoff PM, Morris JS, et al: Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28:453-459, 2010
23. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007
24. Mizukami Y, Jo WS, Duerr EM, et al: Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 11:992-997, 2005
25. Tian J, Lambertz I, Berton TR, et al: Transgenic insulin-like growth factor-1 stimulates activation of COX-2 signaling in mammary glands. Mol Carcinog [epub ahead of print on October 17, 2011]
26. Hilmi C, Guyot M, Pagès G: VEGF spliced variants: Possible role of anti-angiogenesis therapy. J Nucleic Acids 2012:162692, 2012
27. Zhou S, Gu L, He J, et al: MDM2 regulates vascular endothelial growth factor mRNA stabilization in hypoxia. Mol Cell Biol 31:4928-4937, 2011
28. Karar J, Maity A: PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 4:51, 2011
29. Viloria-Petit A, Crombet T, Jothy S, et al: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61:5090-5101, 2001
30. Natale RB, Thongprasert S, Greco FA, et al: Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29:1059-1066, 2011
31. Rubenstein JL, Kim J, Ozawa T, et al: Anti- VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-314, 2000
32. Pàez-Ribes M, Allen E, Hudock J, et al: Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231, 2009
33. Ebos JM, Lee CR, Cruz-Munoz W, et al: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239, 2009
34. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
35. Carmeliet P, Jain RK: Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10:417-427, 2011
36. Eder JP, Vande Woude GF, Boerner SA, et al: Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207-2214, 2009
37. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603, 2008
38. Buckanovich R, Berger R, Sella A, et al: Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 29:334s, 2011 (suppl 15; abstr 5008)
39. Kindler HL, Friberg G, Singh DA, et al: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033-8040, 2005
40. Schneider G, Schmid RM: Genetic alterations in pancreatic carcinoma. Mol Cancer 2:15, 2003
41. Yu JL, Rak JW, Coomber BL, et al: Effect of p53 status on tumor response to antiangiogenic therapy. Science 295:1526-1528, 2002
42. Akakura N, Kobayashi M, Horiuchi I, et al: Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61:6548-6554, 2001
43. De Falco E, Porcelli D, Torella AR, et al: SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 104:3472-3482, 2004
44. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 10:858-864, 2004
45. Yang L, DeBusk LM, Fukuda K, et al: Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409-421, 2004
46. Du R, Lu KV, Petritsch C, et al: HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13:206-220, 2008
47. Aghi M, Cohen KS, Klein RJ, et al: Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res 66:9054-9064, 2006
48. Shojaei F, Wu X, Malik AK, et al: Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 25:911-920, 2007
49. Shojaei F, Wu X, Qu X, et al: G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A 106:6742-6747, 2009
50. Murdoch C, Muthana M, Coffelt SB, et al: The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8:618-631, 2008
51. Fukumura D, Duda DG, Munn LL, et al: Tumor microvasculature and microenvironment: Novel insights through intravital imaging in preclinical models. Microcirculation 17:206-225, 2010
52. Lunt SJ, Chaudary N, Hill RP: The tumor microenvironment and metastatic disease. Clin Exp Metastasis 26:19-34, 2009
53. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91, 1996
54. Tong RT, Boucher Y, Kozin SV, et al: Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736, 2004
55. Stockmann C, Doedens A, Weidemann A, et al: Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456:814-818, 2008
56. Aragonés J, Fraisl P, Baes M, et al: Oxygen sensors at the crossroad of metabolism. Cell Metab 9:11-22, 2009
57. Mazzone M, Dettori D, Leite de Oliveira R, et al: Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136:839-851, 2009
58. Chen SF, Zhang J, Li XB, et al: The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer. Mol Cell Biochem 358:257-263, 2011
59. Thurston G, Noguera-Troise I, Yancopoulos GD: The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 7:327-331, 2007
60. Li JL, Sainson RC, Oon CE, et al: DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 71:6073-6083, 2011
61. Darland DC, Massingham LJ, Smith SR, et al: Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 264:275-288, 2003
62. Song S, Ewald AJ, Stallcup W, et al: PDGFR-beta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 7:870-879, 2005
63. Orlidge A, D'Amore PA: Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 105:1455-1462, 1987
64. Díaz-Flores L, Gutiérrez R, Madrid JF, et al: Pericytes: Morphofunction, interactions and pathology in a quiescent and activated mesenchymal cell niche. Histol Histopathol 24:909-969, 2009
65. Morikawa S, Baluk P, Kaidoh T, et al: Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160:985-1000, 2002
66. Ozawa MG, Yao VJ, Chanthery YH, et al: Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma. Cancer 104:2104-2115, 2005
67. Gerhardt H, Semb H: Pericytes: Gatekeepers in tumour cell metastasis? J Mol Med (Berl) 86:135-144, 2008
68. Greenberg JI, Shields DJ, Barillas SG, et al: A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456:809-813, 2008
69. Winkler F, Kozin SV, Tong RT, et al: Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563, 2004
70. Hamdan R, Zhou Z, Kleinerman ES: SDF-1α induces PDGF-B expression and the differentiation of bone marrow cells into pericytes. Mol Cancer Res 9:1462-1470, 2011
71. Bergers G, Song S, Meyer-Morse N, et al: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295, 2003
72. Lu C, Kamat AA, Lin YG, et al: Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 13:4209-4217, 2007
73. Lu C, Thaker PH, Lin YG, et al: Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 198:477.e1-477.e9, 2008; discussion 477.e9-477.e10
74. Lu C, Shahzad MM, Moreno-Smith M, et al: Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 9:176-182, 2010
75. Hedlund EM, Hosaka K, Zhong Z, et al: Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc Natl Acad Sci U S A 106:17505-17510, 2009
76. Fischer C, Mazzone M, Jonckx B, et al: FLT1 and its ligands VEGFB and PlGF: Drug targets for anti-angiogenic therapy? Nat Rev Cancer 8:942-956, 2008
77. Carmeliet P, Moons L, Luttun A, et al: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7:575-583, 2001
78. Mac Gabhann F, Popel AS: Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am J Physiol Heart Circ Physiol 286:H153-H164, 2004
79. Holash J, Davis S, Papadopoulos N, et al: VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393-11398, 2002
80. Tew WP, Colombo N, Ray-Coquard I, et al: VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): Preliminary results of a randomized, multicenter phase II study. J Clin Oncol 25:276s, 2007 (suppl 18; abstr 5508)
81. Vergote I, Amant F, Advani S, et al: Intravenous aflibercept (VEGF Trap) in advanced ovarian cancer patients with recurrent symptomatic malignant ascites: Main efficacy and safety results of a phase II, randomized, double-blind, placebocontrolled study. Presented at the 16th European Society of Gynaecological Oncology, Belgrade, Serbia, October 11-15, 2009
82. Coleman RL, Duska LR, Ramirez PT, et al: Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 12:1109-1117, 2011
83. Augustin HG, Koh GY, Thurston G, et al: Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 10:165-177, 2009
84. Kaur B, Tan C, Brat DJ, et al: Genetic and hypoxic regulation of angiogenesis in gliomas. J Neurooncol 70:229-243, 2004
85. Berger MS, Wilson CB: The Gliomas. Philadelphia, PA, W.B. Saunders, 1999
86. Norden AD, Young GS, Setayesh K, et al: Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 70:779-787, 2008
87. Narayana A, Kelly P, Golfinos J, et al: Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: Impact on local control and patient survival. J Neurosurg 110:173-180, 2009
88. Akino T, Hida K, Hida Y, et al: Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 175:2657-2667, 2009
89. Xiong YQ, Sun HC, Zhang W, et al: Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 15:4838-4846, 2009
90. Dudley AC, Klagsbrun M: Tumor endothelial cells join the resistance. Clin Cancer Res 15:4787-4789, 2009
91. Sternberg CN, Davis ID, Mardiak J, et al: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 28:1061-1068, 2010
92. Ledermann JA, Hackshaw A, Kaye S, et al: Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 29:3798-3804, 2011
93. Allen E, Walters IB, Hanahan D: Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 17:5299-5310, 2011
94. Herbst RS, Hong D, Chap L, et al: Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27:3557-3565, 2009
95. Karlan BY, Oza AM, Richardson GE, et al: Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 20:362-371, 2012
96. Chang YM, Kung HJ, Evans CP: Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 9:90-100, 2007
97. Mayer EL, Krop IE: Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 16:3526-3532, 2010
98. Bolós V, Gasent JM, López-Tarruella S, et al: The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther 3:83-97, 2010
99. Wheeler DL, Iida M, Dunn EF: The role of Src in solid tumors. Oncologist 14:667-678, 2009
100. Johnson FM, Bekele BN, Feng L, et al: Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:4609-4615, 2010
101. Lu C, Han HD, Mangala LS, et al: Regulation of tumor angiogenesis by EZH2. Cancer Cell 18:185-197, 2010
102. Smits M, Nilsson J, Mir SE, et al: MiR-101 is down-regulated in glioblastoma resulting in EZH2- induced proliferation, migration, and angiogenesis. Oncotarget 1:710-720, 2010
103. Kottakis F, Polytarchou C, Foltopoulou P, et al: FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell 43:285-298, 2011
104. Lippert JW 3rd: Vascular disrupting agents. Bioorg Med Chem 15:605-615, 2007
105. Hori K, Saito S, Kubota K: A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 86:1604-1614, 2002
106. Petrillo M, Borriello M, Fuoco G, et al: Novel VEGF-independent strategies targeting tumor vasculature: Clinical aspects. Curr Pharm Des 18:2702-2712, 2012
107. Taylor M, Billiot F, Marty V, et al: Reversing resistance to vascular-disrupting agents by blocking late mobilization of circulating endothelial progenitor cells. Cancer Discov 2:434-449, 2012
108. Shaked Y, Emmenegger U, Man S, et al: Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 106:3058-3061, 2005
109. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436, 2004
110. Gogas H, Dafni U, Karina M, et al: Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III trial. Breast Cancer Res Treat 132:609-619, 2012
111. Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial. Lancet 374:1331-1338, 2009
112. Fujiwara K, Aotani E, Hamano T, et al: A randomized phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. Jpn J Clin Oncol 41:278-282, 2011
113. Kelly CM, Green MC, Broglio K, et al: Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol 30:930-935, 2012
114. Caporali A, Emanueli C: MicroRNA regulation in angiogenesis. Vascul Pharmacol 55:79-86, 2011
115. Coussens LM, Raymond WW, Bergers G, et al: Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13:1382-1397, 1999
116. de Visser KE, Korets LV, Coussens LM: De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7:411-423, 2005
117. Lin EY, Li JF, Gnatovskiy L, et al: Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66:11238-11246, 2006
118. Burnstock G: Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 22:364-373, 2002
119. Anitua E, Andia I, Ardanza B, et al: Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 91:4-15, 2004
120. Lansdown AB: Calcium: A potential central regulator in wound healing in the skin. Wound Repair Regen 10:271-285, 2002
121. Italiano JE Jr, Richardson JL, Patel-Hett S, et al: Angiogenesis is regulated by a novel mechanism: Pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111:1227-1233, 2008